BioXcel plans an sNDA submission this month for at-home IGALMI, potentially opening a larger market.
Unpriced research observations (excluded from Calls and Returns):
BTAI β WATCH BioXcel announced it will submit an sNDA this month to expand IGALMI approval to at-home use, which the author says is the same approved drug but a much larger market with no FDA-approved at-home options today. If the submission proceeds as planned, approval could come as early as 2026. The author frames this as a high-risk news/momentum play and is watching volume and follow-through closely. resolved_asset_type_mismatch
BioXcel just announced they plan to submit an sNDA this month to get IGALMI approved for at-home use.